- List
- By Topic
- On Map
- Search Details

neuroendocrine tumor
Need help? See RSS Feeds
Choose a feed type:

neuroendocrine tumor (2723 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03271281 | Recruiting | PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT03271281 | AK2017-2 2017-002512-14 |
November 20, 2017 | September 1, 2019 | September 1, 2020 | September 5, 2017 | January 29, 2019 |
|
|||
2 | NCT03278275 | Recruiting | PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT03278275 | AK2017-1 2017-002312-13 |
November 20, 2017 | September 1, 2019 | September 1, 2020 | September 11, 2017 | January 29, 2019 |
|
|||
3 | NCT03335670 | Recruiting | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Early Phase 1 |
|
Other / NIH |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03335670 | 201708705 P50CA174521 |
November 3, 2017 | October 1, 2019 | December 31, 2020 | November 8, 2017 | January 9, 2018 |
|
|||
4 | NCT03372356 | Recruiting | Psychosocial Screening for Neuroendocrine Tumor Patients |
|
Observational |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT03372356 | PSNET | August 9, 2017 | August 9, 2019 | August 9, 2020 | December 13, 2017 | December 13, 2017 |
|
|||||
5 | NCT03478358 | Recruiting | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
20 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03478358 | PekingUMCH-NM018 | April 30, 2017 | August 1, 2018 | August 1, 2018 | March 27, 2018 | March 27, 2018 |
|
|||
6 | NCT03308682 | Recruiting | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 |
|
Other / NIH |
|
|
30 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03308682 | PUMCH-EB-3 ZIAEB000073 |
April 30, 2017 | May 1, 2018 | May 1, 2018 | October 12, 2017 | October 12, 2017 |
|
|||
7 | NCT02691078 | Unknown † | Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
39 | All | 18 Years and older (Adult, Older Adult) | NCT02691078 | LACOG 0214 | July 2016 | July 2018 | February 25, 2016 | August 9, 2016 |
|
||||
8 | NCT02270567 | Active, not recruiting | RegisterNET - A Registry for Neuroendocrine Tumors in the USA |
|
|
Observational |
|
Industry |
|
|
100 | All | 21 Years and older (Adult, Older Adult) | NCT02270567 | WREN_REGISTER_01 | RegisterNET | February 2015 | March 2018 | March 2020 | October 21, 2014 | November 21, 2018 |
|
|||
9 | NCT00985946 | Terminated Has Results |
Study of Panobinostat in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
15 | All | 18 Years and older (Adult, Older Adult) | NCT00985946 | 2010-0050 (CO08209) CLBH589BUS38T |
May 2010 | April 2015 | April 2015 | September 29, 2009 | July 17, 2017 | July 17, 2017 |
|
||
10 | NCT02840149 | Enrolling by invitation | SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
75 | All | 18 Years and older (Adult, Older Adult) | NCT02840149 | CODIM-MDM-16-211 | February 12, 2018 | December 2019 | December 2019 | July 21, 2016 | February 28, 2018 |
|
|||
11 | NCT02743741 | Recruiting | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors |
|
|
Interventional |
Not Applicable |
|
Other / Industry |
|
|
195 | All | Child, Adult, Older Adult | NCT02743741 | OZM-067 | July 2016 | January 2024 | January 2024 | April 19, 2016 | September 26, 2018 |
|
|||
12 | NCT03749681 | Not yet recruiting | Neuroendocrine Tumors of Old Patients in the West of France |
|
Observational |
|
Other / Industry |
|
|
306 | All | 75 Years and older (Older Adult) | NCT03749681 | TANGO (29BRC18.0013) | TANGO | December 2018 | March 28, 2020 | March 28, 2020 | November 21, 2018 | November 21, 2018 |
|
||||
13 | NCT03420521 | Recruiting | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
64 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03420521 | J17156 IRB00151698 |
March 9, 2018 | January 15, 2023 | January 15, 2024 | February 2, 2018 | July 9, 2018 |
|
|||
14 | NCT02489604 | Recruiting | Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
98 | All | 18 Years and older (Adult, Older Adult) | NCT02489604 | IRST100.11 | LUNET | December 2013 | December 2020 | December 2020 | July 3, 2015 | November 9, 2018 |
|
||
15 | NCT02375464 | No longer available | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors |
|
|
Expanded Access |
|
Other | All | Child, Adult, Older Adult | NCT02375464 | 15-0587 | April 2015 | December 2018 | December 2019 | March 2, 2015 | November 8, 2016 | ||||||||
16 | NCT02939651 | Recruiting | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
21 | All | 18 Years and older (Adult, Older Adult) | NCT02939651 | GI-087 | October 26, 2016 | September 2, 2018 | January 2020 | October 20, 2016 | September 26, 2018 |
|
|||
17 | NCT02586844 | Recruiting | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors |
|
Observational |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT02586844 | NET-SEQ | NET-SEQ | October 2013 | October 2020 | October 2020 | October 26, 2015 | November 14, 2017 |
|
||||
18 | NCT00424723 | Completed | Pemetrexed in Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT00424723 | 05-309 | December 2005 | January 2007 | March 2010 | January 19, 2007 | August 12, 2010 |
|
|||
19 | NCT02624154 | Unknown † | Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival |
|
|
Observational |
|
Other |
|
|
2 | All | 10 Years to 80 Years (Child, Adult, Older Adult) | NCT02624154 | SYSU 211 | December 2015 | June 2016 | December 2016 | December 8, 2015 | December 8, 2015 | |||||
20 | NCT00942682 | Completed | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
21 | All | 18 Years and older (Adult, Older Adult) | NCT00942682 | 09-094 | July 2009 | March 2013 | March 2013 | July 21, 2009 | April 29, 2014 |
|
|||
21 | NCT03143946 | Recruiting | DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
53 | All | 18 Years and older (Adult, Older Adult) | NCT03143946 | 201600626 | December 2016 | December 2018 | December 2018 | May 8, 2017 | October 12, 2018 |
|
|||
22 | NCT03136328 | Completed Has Results |
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
11 | All | 18 Years and older (Adult, Older Adult) | NCT03136328 | 15-06-274 | May 16, 2016 | March 2017 | March 2017 | May 2, 2017 | January 30, 2019 | January 30, 2019 | |||
23 | NCT02678780 | Completed | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
111 | All | 18 Years and older (Adult, Older Adult) | NCT02678780 | GETNE1509 2015-001467-39 |
TALENT | October 2015 | December 2017 | February 10, 2016 | January 17, 2018 |
|
|||
24 | NCT03197012 | Recruiting | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor |
|
|
Interventional |
Early Phase 1 |
|
Other |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT03197012 | CC# 17455 | July 1, 2017 | July 1, 2020 | July 1, 2021 | June 23, 2017 | August 1, 2017 |
|
|||
25 | NCT02075606 | Completed | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients |
|
|
Interventional |
Phase 4 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Older Adult) | NCT02075606 | A-97-52030-270 | CALM-NET | May 2014 | June 2017 | June 2017 | March 3, 2014 | October 2, 2017 |
|
||
26 | NCT01099540 | Completed | Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
37 | All | 18 Years and older (Adult, Older Adult) | NCT01099540 | 2009-09-090 | April 2010 | March 2012 | March 2013 | April 7, 2010 | December 29, 2015 |
|
|||
27 | NCT01099228 | Completed | Combination Targeted Radiotherapy in Neuroendocrine Tumors |
|
|
Interventional |
Not Applicable |
|
Other / U.S. Fed |
|
|
2 | All | 18 Years and older (Adult, Older Adult) | NCT01099228 | 200602763 | September 2006 | April 2008 | July 2015 | April 6, 2010 | July 21, 2016 |
|
|||
28 | NCT02147106 | Completed | Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study |
|
|
Observational |
|
Other |
|
|
26 | All | 18 Years and older (Adult, Older Adult) | NCT02147106 | VIDEO-NET-2014 | VIDEO-NET | May 2014 | March 2017 | March 2017 | May 26, 2014 | May 5, 2017 |
|
|||
29 | NCT02279758 | Unknown † | A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
30 | All | 16 Years and older (Child, Adult, Older Adult) | NCT02279758 | NP 515/2014 | MetNet | March 2014 | December 2017 | October 31, 2014 | October 31, 2014 |
|
|||
30 | NCT01747096 | Completed | TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
130 | All | 18 Years and older (Adult, Older Adult) | NCT01747096 | BRD/11/05-K | 68-DOTANOC-GEP | November 2012 | May 2016 | May 2016 | December 11, 2012 | July 29, 2016 |
|
||
31 | NCT01338090 | Completed | 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors |
|
|
Observational |
|
Other / Industry |
|
|
14 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT01338090 | 20091104 2009-017195-24 |
NETPET | April 2010 | March 2012 | March 2012 | April 19, 2011 | April 3, 2012 |
|
|||
32 | NCT00137774 | Completed | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
34 | All | 18 Years and older (Adult, Older Adult) | NCT00137774 | 04-272 | November 2004 | July 2005 | December 2012 | August 30, 2005 | April 9, 2013 |
|
|||
33 | NCT00165230 | Completed | Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT00165230 | 02-011 | May 2002 | July 2006 | July 2006 | September 14, 2005 | April 28, 2009 |
|
|||
34 | NCT03288597 | Recruiting | Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms |
|
|
Observational |
|
Other |
|
|
146 | All | 18 Years and older (Adult, Older Adult) | NCT03288597 | 68Ga&FDG PET/CT | September 1, 2017 | September 1, 2018 | September 1, 2020 | September 20, 2017 | September 20, 2017 |
|
||||
35 | NCT00569738 | Unknown † | Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors |
|
|
Observational |
|
Other |
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT00569738 | 061267-HMO-CTIL Imaging of NE Tumors |
December 2008 | December 2010 | December 7, 2007 | February 17, 2009 |
|
||||||
36 | NCT02455596 | Unknown † | Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT02455596 | JH-NETs-001 | May 2015 | October 2016 | December 2016 | May 28, 2015 | January 5, 2016 |
|
|||
37 | NCT02539433 | Completed | Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
22 | All | 23 Years to 81 Years (Adult, Older Adult) | NCT02539433 | IRB #03-117 | December 2003 | May 2015 | May 2015 | September 3, 2015 | September 3, 2015 |
|
|||
38 | NCT00851604 | Unknown † | ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors |
|
Observational |
|
Other |
|
40 | All | 18 Years to 90 Years (Adult, Older Adult) | NCT00851604 | 052508-HMO-CTIL | March 2009 | March 2010 | January 2011 | February 26, 2009 | June 3, 2010 |
|
||||||
39 | NCT02507908 | Completed | 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor' |
|
Observational |
|
Other |
|
|
59 | All | 18 Years and older (Adult, Older Adult) | NCT02507908 | 201500365 | 5-HIAA | July 2015 | May 2017 | May 2017 | July 24, 2015 | May 5, 2017 |
|
||||
40 | NCT02779257 | Withdrawn | Pasireotide Treatment for Neuroendocrine Tumor |
|
|
Interventional |
Phase 4 |
|
Other / Industry |
|
|
0 | Male | 18 Years to 75 Years (Adult, Older Adult) | NCT02779257 | HP-00069513EU | April 2016 | June 2016 | June 2016 | May 20, 2016 | June 8, 2016 | ||||
41 | NCT03204032 | Recruiting | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03204032 | CH-GI-104 | October 2016 | October 2017 | September 2018 | June 29, 2017 | June 29, 2017 |
|
|||
42 | NCT01039922 | Recruiting | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland |
|
Observational |
|
Other / Industry |
|
|
1245 | All | Child, Adult, Older Adult | NCT01039922 | BAG 035.0002-20/19 395/2014 |
SwissNET | January 2008 | January 2028 | January 2028 | December 25, 2009 | January 14, 2019 |
|
||||
43 | NCT03592940 | Completed | The Management of Neuroendocrine Tumours: A Nutritional Viewpoint. |
|
|
Observational |
|
Other |
|
|
100 | All | 18 Years to 60 Years (Adult) | NCT03592940 | 201/17 | NetNutr | November 1, 2017 | December 1, 2017 | June 30, 2018 | July 19, 2018 | July 19, 2018 |
|
|||
44 | NCT02826928 | Recruiting | Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
120 | All | 18 Years to 99 Years (Adult, Older Adult) | NCT02826928 | PO15138 | October 26, 2016 | October 31, 2019 | January 2020 | July 11, 2016 | June 15, 2018 |
|
|||
45 | NCT03204019 | Recruiting | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03204019 | CH-GI-103 | October 2016 | October 2017 | September 2018 | June 29, 2017 | June 29, 2017 |
|
|||
46 | NCT03724409 | Recruiting | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases |
|
|
Interventional |
Early Phase 1 |
|
Other / NIH |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT03724409 | 201805910 P50CA174521 |
October 11, 2018 | December 2025 | December 2025 | October 30, 2018 | October 30, 2018 |
|
|||
47 | NCT02420691 | Active, not recruiting | LEE011 in Neuroendocrine Tumors of Foregut Origin |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
21 | All | 18 Years and older (Adult, Older Adult) | NCT02420691 | 2014-0371 NCI-2015-01017 |
August 2015 | August 2019 | August 2019 | April 20, 2015 | January 30, 2019 |
|
|||
48 | NCT00501540 | Completed Has Results |
Lithium for Low-Grade Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other / NIH |
|
|
15 | All | 18 Years and older (Adult, Older Adult) | NCT00501540 | CO07203 R21CA117117-01A2 2007-0065 NCI-2011-00616 |
July 2007 | June 2009 | June 2009 | July 16, 2007 | May 3, 2017 | May 3, 2017 |
|
||
49 | NCT01398306 | Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. |
|
|
Observational |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT01398306 | 230520112 | BANN | July 2011 | April 2012 | April 2012 | July 20, 2011 | May 8, 2012 |
|
|||
50 | NCT03217097 | Recruiting | MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents |
|
|
Interventional |
Phase 4 |
|
Other |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT03217097 | 69HCL17_0284 | MGMT-NET | October 16, 2018 | July 2021 | November 2021 | July 13, 2017 | January 23, 2019 |
|
||
51 | NCT03130205 | Recruiting | Biomarker Study in Pancreatic Neuroendocrine Tumours |
|
|
Observational |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03130205 | Uppsala University Hospital | PROGRESS | May 1, 2017 | January 1, 2021 | January 1, 2022 | April 26, 2017 | August 25, 2017 |
|
|||
52 | NCT03629847 | Recruiting | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03629847 | 2121-159 | December 2012 | December 2018 | December 2018 | August 14, 2018 | August 14, 2018 |
|
|||
53 | NCT03014297 | Active, not recruiting | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03014297 | MCC-16-GI-99-PMC | March 6, 2017 | February 28, 2019 | June 30, 2019 | January 9, 2017 | October 29, 2018 |
|
|||
54 | NCT03741517 | Recruiting | Biomarker Study of Pancreatic Neuroendocrine Tumours |
|
|
Observational |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03741517 | PRORESS pancreas | January 30, 2019 | December 31, 2022 | December 31, 2022 | November 15, 2018 | January 31, 2019 |
|
||||
55 | NCT03112694 | Completed | Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors |
|
|
Observational |
|
Industry |
|
|
93 | All | 18 Years and older (Adult, Older Adult) | NCT03112694 | A-US-52030-364 | April 4, 2017 | November 2, 2017 | November 2, 2017 | April 13, 2017 | December 21, 2018 |
|
||||
56 | NCT03673943 | Recruiting | Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
59 | All | 18 Years and older (Adult, Older Adult) | NCT03673943 | 131797 | August 23, 2018 | August 23, 2019 | August 23, 2019 | September 17, 2018 | September 17, 2018 |
|
|||
57 | NCT03576040 | Not yet recruiting | Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors |
|
|
Observational |
|
Other |
|
|
120 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03576040 | GAPET-NET (29BRC17.0036) | GAPET-NET | July 1, 2018 | July 2023 | July 2023 | July 3, 2018 | July 3, 2018 |
|
|||
58 | NCT03167853 | Recruiting | Study of JS001 in Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03167853 | HMO-JS001-Ib-NEC-02 | April 6, 2017 | December 2018 | June 2019 | May 30, 2017 | September 5, 2018 |
|
|||
59 | NCT02749331 | Recruiting | Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
35 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT02749331 | VIRUSNET201401 2014-000614-64 |
RADNET | March 2016 | August 2020 | December 2020 | April 22, 2016 | October 4, 2018 |
|
||
60 | NCT02288377 | Recruiting | A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
118 | All | 18 Years and older (Adult, Older Adult) | NCT02288377 | PRODIGE31 | REMINET | January 2015 | December 2019 | January 2024 | November 11, 2014 | June 13, 2018 |
|
||
61 | NCT02092714 | Recruiting | Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors |
|
|
Observational |
|
Other / NIH |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT02092714 | CGI-061 NCI-2013-01950 13-040 P30CA006927 |
October 16, 2013 | November 2018 | November 16, 2019 | March 20, 2014 | February 26, 2018 |
|
||||
62 | NCT02588170 | Recruiting | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
273 | All | 18 Years and older (Adult, Older Adult) | NCT02588170 | 2015-012-00CH4 | December 7, 2015 | June 2019 | December 2019 | October 27, 2015 | November 12, 2018 |
|
|||
63 | NCT03279601 | Recruiting | Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
148 | All | 18 Years and older (Adult, Older Adult) | NCT03279601 | CAPDTIC vs. CAPTEM | September 1, 2017 | September 1, 2019 | September 1, 2020 | September 12, 2017 | September 12, 2017 |
|
|||
64 | NCT00056693 | Completed | Treatment With SU11248 in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
107 | All | 18 Years and older (Adult, Older Adult) | NCT00056693 | RTKC-0511-015 | April 2003 | September 2006 | September 2006 | March 24, 2003 | July 21, 2008 |
|
|||
65 | NCT02788578 | Terminated | A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours |
|
Observational |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT02788578 | F-FR-52030-344 | PRELUDE | June 2016 | July 2017 | July 2017 | June 2, 2016 | December 21, 2018 |
|
||||
66 | NCT03034200 | Recruiting | Phase 2 Study of ONC201 in Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
24 | All | 18 Years and older (Adult, Older Adult) | NCT03034200 | CASE2716 | August 2, 2017 | June 2019 | June 2019 | January 27, 2017 | February 15, 2019 |
|
|||
67 | NCT01364415 | Completed | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
29 | All | 18 Years and older (Adult, Older Adult) | NCT01364415 | CSOM230D2101 | August 2011 | April 2016 | April 2016 | June 2, 2011 | June 28, 2016 |
|
|||
68 | NCT02609737 | Active, not recruiting | Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT02609737 | 15-161 | November 13, 2015 | November 2019 | November 2019 | November 20, 2015 | April 26, 2018 |
|
|||
69 | NCT03670030 | Recruiting | A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
10 | All | 18 Years and older (Adult, Older Adult) | NCT03670030 | NET-001 | November 5, 2018 | May 1, 2020 | November 1, 2020 | September 13, 2018 | February 8, 2019 |
|
|||
70 | NCT02267967 | Completed | Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
81 | All | 18 Years and older (Adult, Older Adult) | NCT02267967 | 2014-012-00CH1 | October 31, 2014 | August 23, 2017 | August 23, 2017 | October 20, 2014 | November 12, 2018 |
|
|||
71 | NCT03511768 | Recruiting | A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
65 | All | 18 Years and older (Adult, Older Adult) | NCT03511768 | 201801001 | January 2, 2018 | December 30, 2019 | December 30, 2020 | April 30, 2018 | April 30, 2018 |
|
|||
72 | NCT01994213 | Terminated | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Industry / Other |
|
|
53 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT01994213 | FMTN- Ⅱ- GEPNET | October 2011 | November 2015 | May 2016 | November 25, 2013 | January 21, 2019 |
|
|||
73 | NCT02472678 | Completed | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
91 | All | 18 Years to 90 Years (Adult, Older Adult) | NCT02472678 | 20150501 | WIN | May 2015 | May 2017 | May 2017 | June 16, 2015 | May 5, 2017 |
|
||
74 | NCT02698410 | Active, not recruiting | Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT02698410 | A-93-52030-325 2014-005579-10 |
ATLANT | July 2016 | March 2019 | June 2019 | March 3, 2016 | February 1, 2019 |
|
||
75 | NCT02589821 | Recruiting | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
195 | All | 18 Years and older (Adult, Older Adult) | NCT02589821 | 2015-012-00CH3 | December 7, 2015 | March 2019 | December 2019 | October 28, 2015 | November 12, 2018 |
|
|||
76 | NCT03053999 | Recruiting | Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) |
|
|
Observational |
|
Other |
|
|
53 | All | Child, Adult, Older Adult | NCT03053999 | PA12-0892 | October 9, 2012 | October 2022 | October 2023 | February 15, 2017 | February 14, 2018 |
|
||||
77 | NCT01658436 | Completed Has Results |
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
31 | All | 18 Years and older (Adult, Older Adult) | NCT01658436 | CBEZ235F2201 2012-000675-16 |
November 2012 | July 2015 | July 2015 | August 7, 2012 | May 2, 2016 | May 2, 2016 |
|
||
78 | NCT01967537 | Active, not recruiting | Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
NIH |
|
|
337 | All | 10 Years to 99 Years (Child, Adult, Older Adult) | NCT01967537 | 130193 13-C-0193 |
October 18, 2013 | December 17, 2017 | December 3, 2022 | October 23, 2013 | February 14, 2018 |
|
|||
79 | NCT02132468 | Completed Has Results |
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
18 | All | 18 Years and older (Adult, Older Adult) | NCT02132468 | OX4218s | GI-NETorPNET | September 2014 | June 2016 | August 2016 | May 7, 2014 | December 5, 2017 | October 19, 2017 |
|
|
80 | NCT03667092 | Recruiting | Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Older Adult) | NCT03667092 | RC31/17/0356 | GENEBIOLuNET | September 1, 2018 | August 2021 | December 2021 | September 12, 2018 | September 12, 2018 |
|
||
81 | NCT02693067 | Recruiting | A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
12 | All | 18 Years and older (Adult, Older Adult) | NCT02693067 | PV-10-NET-01 | July 2016 | July 2020 | August 2020 | February 26, 2016 | April 7, 2017 |
|
|||
82 | NCT00815620 | Completed | Best Therapy for Patients With Neuroendocrine Tumors |
|
Observational |
|
Other |
|
|
150 | All | 18 Years to 90 Years (Adult, Older Adult) | NCT00815620 | ZBB-NET-1 | BESTTHERAPYNET | November 2008 | August 2016 | March 2017 | December 30, 2008 | March 21, 2017 |
|
||||
83 | NCT01628913 | Terminated Has Results |
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
62 | All | 18 Years and older (Adult, Older Adult) | NCT01628913 | CBEZ235Z2401 2012-000769-19 |
October 2012 | September 2014 | September 2014 | June 27, 2012 | April 7, 2016 | April 7, 2016 |
|
||
84 | NCT01845675 | Completed | Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
14 | All | 18 Years and older (Adult, Older Adult) | NCT01845675 | TEPNET | April 2013 | November 30, 2016 | March 31, 2017 | May 3, 2013 | April 13, 2017 |
|
|||
85 | NCT02683941 | Active, not recruiting | Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
216 | All | 18 Years and older (Adult, Older Adult) | NCT02683941 | A-US-52030-328 2015-004992-62 |
SPINET | February 2016 | August 2019 | August 2019 | February 17, 2016 | December 21, 2018 |
|
||
86 | NCT02125474 | Recruiting | Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
39 | All | 18 Years to 90 Years (Adult, Older Adult) | NCT02125474 | C41030610-041 | November 2013 | October 2019 | October 2019 | April 29, 2014 | October 10, 2016 |
|
|||
87 | NCT01121562 | Completed Has Results |
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
12 | All | 20 Years and older (Adult, Older Adult) | NCT01121562 | A6181193 | July 2010 | July 2011 | November 2013 | May 12, 2010 | June 30, 2014 | August 27, 2012 |
|
||
88 | NCT02815969 | Active, not recruiting | The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors |
|
|
Observational |
|
Other |
|
|
210 | All | 18 Years and older (Adult, Older Adult) | NCT02815969 | 201600496 | September 2016 | January 2020 | January 2020 | June 28, 2016 | October 12, 2018 |
|
||||
89 | NCT01673906 | Completed | 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
142 | All | 18 Years to 90 Years (Adult, Older Adult) | NCT01673906 | 2012-000994-22 | August 2012 | August 2015 | July 5, 2016 | August 28, 2012 | March 9, 2018 |
|
|||
90 | NCT01525550 | Completed Has Results |
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 4 |
|
Industry |
|
|
106 | All | 18 Years and older (Adult, Older Adult) | NCT01525550 | A6181202 2011-004363-74 |
June 6, 2012 | March 19, 2016 | July 26, 2018 | February 3, 2012 | September 26, 2018 | May 19, 2017 |
|
||
91 | NCT01931488 | Unknown † | 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT01931488 | TASMC-12-ES-0341-CTIL | August 2013 | January 2015 | January 2016 | August 29, 2013 | August 29, 2013 |
|
|||
92 | NCT02134639 | Completed | PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation |
|
|
Observational |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT02134639 | CHUBX2012/28 2013-003927-12 |
GALTEP | September 2014 | December 2014 | January 2015 | May 9, 2014 | August 4, 2017 |
|
|||
93 | NCT02713763 | Recruiting | Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT02713763 | GETNE-2016-01 2015-005774-37 |
RESUNET | February 14, 2017 | April 2019 | July 2019 | March 21, 2016 | February 7, 2019 |
|
||
94 | NCT01324492 | Completed | Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
16 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT01324492 | CRAD001KCN01 | \MACS1304 | December 2010 | June 2014 | June 2014 | March 29, 2011 | December 30, 2014 |
|
||
95 | NCT02736448 | Recruiting | 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
176 | All | 19 Years and older (Adult, Older Adult) | NCT02736448 | IRST100.17 2014-003067-38 |
Lu-Ca-S | May 2016 | April 2021 | April 2021 | April 13, 2016 | January 16, 2018 |
|
||
96 | NCT02359500 | Terminated | 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
71 | All | 18 Years and older (Adult, Older Adult) | NCT02359500 | GCO 14-2008 | December 2014 | January 23, 2017 | January 23, 2017 | February 10, 2015 | May 3, 2017 |
|
|||
97 | NCT01175096 | Unknown † | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT01175096 | CRAD001KCN01 | July 2010 | January 2012 | January 2012 | August 4, 2010 | August 4, 2010 |
|
|||
98 | NCT02078843 | Terminated | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
54 | All | 18 Years and older (Adult, Older Adult) | NCT02078843 | 092/11 | GaIN | March 2014 | August 2016 | August 2016 | March 5, 2014 | September 7, 2016 |
|
||
99 | NCT03044977 | Recruiting | Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors |
|
|
Interventional |
Early Phase 1 |
|
Other / NIH |
|
|
20 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03044977 | 201608857 P50CA174521-02 |
May 7, 2017 | December 31, 2020 | December 31, 2022 | February 7, 2017 | April 17, 2018 |
|
|||
100 | NCT03457844 | Recruiting | A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3 |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
60 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03457844 | ALTN-13-II | January 30, 2018 | August 30, 2019 | August 30, 2019 | March 8, 2018 | September 11, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.